Literature DB >> 24726725

Wild type p53 reactivation: from lab bench to clinic.

Galina Selivanova1.   

Abstract

The p53 tumor suppressor is the most frequently inactivated gene in cancer. Several mouse models have demonstrated that the reconstitution of the p53 function suppresses the growth of established tumors. These facts, taken together, promote the idea of p53 reactivation as a strategy to combat cancer. This review will focus on recent advances in the development of small molecules which restore the function of wild type p53 by blocking its inhibitors Mdm2 and MdmX or their upstream regulators and discuss the impact of different p53 functions for tumor prevention and tumor eradication. Finally, the recent progress in p53 research will be analyzed concerning the role of p53 cofactors and cellular environment in the biological response upon p53 reactivation and how this can be applied in clinic.
Copyright © 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Apoptosis; Mdm2; MdmX; ROS; Small molecule; p53

Mesh:

Substances:

Year:  2014        PMID: 24726725     DOI: 10.1016/j.febslet.2014.03.049

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  30 in total

1.  Role of gambogic acid and NaI131 in A549/DDP cells.

Authors:  Jing Huang; Xiaoli Zhu; Huan Wang; Shuhua Han; Lu Liu; Yan Xie; Daozhen Chen; Qiang Zhang; Li Zhang; Yue Hu
Journal:  Oncol Lett       Date:  2016-11-25       Impact factor: 2.967

2.  Decreased DNA Damage and Improved p53 Specificity of RITA Analogs.

Authors:  Yue Zhan; Xiaolei Zhou; Sylvain Peuget; Madhurendra Singh; Brian D Peyser; Zhimin Fan; Galina Selivanova
Journal:  Mol Cancer Ther       Date:  2022-10-07       Impact factor: 6.009

3.  DZNep represses Bcl-2 expression and modulates apoptosis sensitivity in response to Nutlin-3a.

Authors:  Yalu Zhou; Ricardo E Perez; Lei Duan; Carl G Maki
Journal:  Cancer Biol Ther       Date:  2018-03-13       Impact factor: 4.742

Review 4.  Aggregation and Prion-Like Properties of Misfolded Tumor Suppressors: Is Cancer a Prion Disease?

Authors:  Danielly C F Costa; Guilherme A P de Oliveira; Elio A Cino; Iaci N Soares; Luciana P Rangel; Jerson L Silva
Journal:  Cold Spring Harb Perspect Biol       Date:  2016-10-03       Impact factor: 10.005

5.  Indolo-pyrido-isoquinolin based alkaloid inhibits growth, invasion and migration of breast cancer cells via activation of p53-miR34a axis.

Authors:  Dimiter B Avtanski; Arumugam Nagalingam; Joseph E Tomaszewski; Prabhakar Risbood; Michael J Difillippantonio; Neeraj K Saxena; Sanjay V Malhotra; Dipali Sharma
Journal:  Mol Oncol       Date:  2016-05-20       Impact factor: 6.603

6.  Nutlin-Induced Apoptosis Is Specified by a Translation Program Regulated by PCBP2 and DHX30.

Authors:  Dario Rizzotto; Sara Zaccara; Annalisa Rossi; Matthew D Galbraith; Zdenek Andrysik; Ahwan Pandey; Kelly D Sullivan; Alessandro Quattrone; Joaquín M Espinosa; Erik Dassi; Alberto Inga
Journal:  Cell Rep       Date:  2020-03-31       Impact factor: 9.423

7.  Medical ozone induces proliferation and migration inhibition through ROS accumulation and PI3K/AKT/NF-κB suppression in human liver cancer cells in vitro.

Authors:  J Li; T Zeng; S Tang; M Zhong; Q Huang; X Li; X He
Journal:  Clin Transl Oncol       Date:  2021-04-05       Impact factor: 3.405

8.  p53 Calls upon CIA (Calcium Induced Apoptosis) to Counter Stress.

Authors:  Sue Haupt; Dinesh Raghu; Ygal Haupt
Journal:  Front Oncol       Date:  2015-03-10       Impact factor: 6.244

Review 9.  Dysregulated transcriptional and post-translational control of DNA methyltransferases in cancer.

Authors:  Ruo-Kai Lin; Yi-Ching Wang
Journal:  Cell Biosci       Date:  2014-08-19       Impact factor: 7.133

Review 10.  β1 Integrins as Therapeutic Targets to Disrupt Hallmarks of Cancer.

Authors:  Anne-Florence Blandin; Guillaume Renner; Maxime Lehmann; Isabelle Lelong-Rebel; Sophie Martin; Monique Dontenwill
Journal:  Front Pharmacol       Date:  2015-11-24       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.